Canadian Sec - Delayed Quote CAD

Braxia Scientific Corp. (BRAX.CN)

0.0050

0.0000

(0.00%)

At close: August 2 at 2:14:34 PM EDT

Braxia Scientific Announces Change in Directors and CEO

Toronto, Ontario--(Newsfile Corp. - November 18, 2024) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) ("Braxia", or the "Company") announced that Jerry Habuda has resigned as a director effective November 12, 2024. Peter Rizakos was appointed on the same date by the remaining directors. Roger McIntyre resigned as a director and CEO effective November 13, 2024. The current directors of the Company are Ahmed Shehata and Peter Rizakos. About Braxia Scientific ...

Newsfile last month

BRAXF
Braxia Scientific Announces Voting Results from the Annual General and Special Meeting of Shareholders

Sale of Company's Assets Approved Toronto, Ontario--(Newsfile Corp. - October 10, 2024) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) ("Braxia", or the "Company"), is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders held on Wednesday, October 9, 2024. A total of 9.9% of the issued and outstanding common shares of the Company were represented either in person or by proxy at the meeting.On a ...

Newsfile 3 months ago

BRAXF
Braxia Announces Annual General and Special Meeting

Toronto, Ontario--(Newsfile Corp. - September 10, 2024) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) ("Braxia Scientific", or the "Company") announced today that an annual general and special meeting (the "Meeting") of the common shareholders will be held in person at 10:00 a.m. (Toronto time) on Wednesday October 9, 2024, at 1430 Hurontario Street, Mississauga, Ontario, L5G 3H4.Please note that shareholders will not be entitled to vote at, or otherwise participate ...

Newsfile 3 months ago

BRAXF
Braxia Scientific Announces Cease Trade Order

Toronto, Ontario--(Newsfile Corp. - August 5, 2024) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FWB: 4960), ("Braxia Scientific", or the "Company"), today announced that the Ontario Securities Commission (the "OSC") issued a failure-to-file cease trade order (the "FFCTO") to the Company on August 2, 2024.The FFCTO is a result of the Company's failure to file its audited annual financial statements (the "Annual Financial Statements"), management discussion and analysis ("MD&A") and c

Newsfile 5 months ago

BRAXF
Braxia Scientific Provides Update on Application for Management Cease Trade Order

Toronto, Ontario--(Newsfile Corp. - July 25, 2024) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) ("Braxia Scientific", or the "Company"), today announced further to its press release of July 15, 2024, that the Ontario Securities Commission (the "OSC") has denied the Company's application for a voluntary management cease trade order (the "MCTO") under National Policy 12-203 Management Cease Trade Orders ("NP 12-203") as the Company does not meet the criteria for ...

Newsfile 5 months ago

BRAXF
Braxia Scientific Announces Application for a Management Cease Trade Order For Late Filing of Audited Annual Financial Statements

Toronto, Ontario--(Newsfile Corp. - July 15, 2024) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960), ("Braxia Scientific", or the "Company"), today announced that it has made an application to the Ontario Securities Commission to approve a management cease trade order ("MCTO") under National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203"), which, if granted, will prohibit the Chief Executive Officer and Chief Financial Officer of the Company

Newsfile 5 months ago

BRAXF
Braxia Scientific Reports Q3 2024 Financial Results

Toronto, Ontario--(Newsfile Corp. - February 29, 2024) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960), ("Braxia Scientific", or the "Company"), a medical research company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the filing of its financial statements and management discussion and analysis for the three months and nine months ended December 31, 2023. Complete financial statements along with rela

Newsfile 10 months ago

BRAXF
Braxia Scientific Reports Mandatory Conversion of Debentures

Toronto, Ontario--(Newsfile Corp. - January 15, 2024) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960), ("Braxia Scientific", or the "Company"), a medical research company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the mandatory conversion of $2,935,714 in convertible debentures, which matured on December 31, 2023, into 19,571,411 common shares at a conversion price of $0.15 per common share.About

Newsfile 11 months ago

BRAXF

Performance Overview

Return	BRAX.CN	S&P/TSX Composite index
YTD	0.00%	+0.60%
1-Year	-50.00%	+18.10%
3-Year	-92.86%	+17.47%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Braxia Scientific Corp. (BRAX.CN)

Braxia Scientific Announces Change in Directors and CEO

Braxia Scientific Announces Voting Results from the Annual General and Special Meeting of Shareholders

Braxia Announces Annual General and Special Meeting

Braxia Scientific Announces Cease Trade Order

Braxia Scientific Provides Update on Application for Management Cease Trade Order

Braxia Scientific Announces Application for a Management Cease Trade Order For Late Filing of Audited Annual Financial Statements

Braxia Scientific Reports Q3 2024 Financial Results

Braxia Scientific Reports Mandatory Conversion of Debentures

Performance Overview